What it's for (Indications)
- Beraprost is primarily indicated for the treatment of pulmonary arterial hypertension (PAH) in patients classified as WHO functional class II, III, or IV, to improve exercise capacity and delay clinical worsening.
- It is a synthetic prostacyclin analogue used in some regions for the management of chronic arterial occlusion (CAO), including conditions such as Buerger's disease and arteriosclerosis obliterans, aiming to alleviate ischemic symptoms like ulcers, rest pain, and cold sensation in the extremities.
- Furthermore, in specific clinical contexts, it may be utilized for the improvement of ischemic symptoms associated with systemic sclerosis and diabetes mellitus where microcirculatory impairment plays a significant role.
- Its use is typically considered in patients who are not candidates for or have not responded to other forms of therapy, or as an adjunct.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | The dosage of beraprost, typically administered orally, varies based on the specific indication and patient tolerability. For pulmonary arterial hypertension (PAH), the usual starting dose is often 20 micrograms (mcg) administered three times daily, usually taken after meals to minimize gastrointestinal discomfort. The dose may be gradually titrated upwards based on the patient's clinical response and tolerability, with increments determined by the treating physician. For chronic arterial occlusion, the standard oral dosage is typically 20 mcg administered three times daily. It is crucial to adhere strictly to the prescribed dosing regimen and to avoid abrupt discontinuation, as this can lead to a rebound phenomenon and worsening of symptoms. Dose adjustments may be necessary in patients with renal or hepatic impairment, requiring careful clinical monitoring. |
Safety & Warnings
Common Side Effects
- Beraprost, being a potent vasodilator, commonly induces side effects related to its pharmacological action.
- The most frequently reported adverse reactions include headache, flushing (warmth and redness of the skin), and jaw pain.
- Other common side effects include dizziness, nausea, diarrhea, and abdominal discomfort.
- Patients may also experience hypotension, palpitations, and peripheral edema.
- Less common but potentially serious side effects can include tachycardia, syncope (fainting), and a heightened risk of bleeding due to its antiplatelet properties.
- Rashes, itching, and other hypersensitivity reactions have also been reported.
- Any severe or persistent side effects should be promptly reported to a healthcare professional, and patients should be monitored for signs of fluid retention or worsening heart failure.
Serious Warnings
- Black Box Warning: **Serious Warnings for Beraprost** While beraprost does not carry an explicit FDA-mandated Black Box Warning in the United States, its use is associated with significant risks that necessitate careful patient selection, monitoring, and management. 1. **Risk of Profound Hypotension:** Beraprost is a potent vasodilator and can cause significant systemic hypotension, particularly upon initiation or dose escalation. This effect can be severe and may lead to syncope, especially in patients with pre-existing low blood pressure or those receiving concomitant antihypertensive agents or other vasodilators. Patients should be educated on symptoms of hypotension and instructed to report them immediately. 2. **Increased Risk of Bleeding:** Due to its antiplatelet properties, beraprost can increase the risk of bleeding. This risk is amplified in patients concurrently taking anticoagulants (e.g., warfarin), antiplatelet agents (e.g., aspirin, clopidogrel), or those with underlying hemorrhagic diatheses. Careful assessment of bleeding risk and close monitoring for signs of hemorrhage are paramount during therapy. 3. **Rebound Pulmonary Hypertension Upon Abrupt Discontinuation:** Sudden cessation or rapid dose reduction of beraprost can precipitate a rapid and severe worsening of pulmonary hypertension symptoms, potentially leading to clinical deterioration and life-threatening events. Therapy with beraprost should always be tapered gradually under the supervision of a physician experienced in managing pulmonary arterial hypertension. 4. **Fluid Retention and Cardiac Decompensation:** Beraprost may lead to or exacerbate fluid retention and peripheral edema. Patients with underlying cardiovascular conditions, particularly heart failure, require vigilant monitoring for signs of volume overload or cardiac decompensation. These serious warnings underscore the importance of expert clinical judgment and continuous patient surveillance throughout the course of beraprost treatment.
- Patients receiving beraprost must be carefully monitored due to several significant warnings.
- **Hypotension:** Beraprost can cause symptomatic systemic hypotension, especially during initiation or dose escalation.
- Blood pressure should be monitored regularly, and caution is advised when co-administering with other vasodilators or antihypertensive agents.
- **Bleeding Risk:** As a prostaglandin I2 analogue with antiplatelet effects, beraprost increases the risk of bleeding.
- This risk is elevated when used concurrently with anticoagulants (e.
- g.
- , warfarin) or other antiplatelet agents (e.
- g.
- , aspirin, clopidogrel).
- Patients should be advised to report any signs of unusual bleeding or bruising.
- **Rebound Pulmonary Hypertension:** Abrupt discontinuation of beraprost can lead to a rebound phenomenon, causing a rapid and severe worsening of pulmonary hypertension and associated symptoms.
- Therefore, the drug should be tapered gradually under medical supervision.
- **Fluid Retention and Heart Failure:** Beraprost may cause or exacerbate fluid retention and peripheral edema.
- Patients with pre-existing heart failure should be closely monitored for signs of decompensation.
- **Hepatic and Renal Impairment:** Patients with severe hepatic or renal dysfunction may require dose adjustments due to altered drug metabolism and excretion, necessitating careful monitoring of drug levels and clinical response.
How it Works (Mechanism of Action)
Beraprost is a synthetic benzindene derivative of prostacyclin (PGI2), a potent endogenous vasodilator and inhibitor of platelet aggregation. Its primary mechanism of action involves binding to and activating specific prostacyclin receptors on vascular smooth muscle cells. This activation leads to the stimulation of adenylyl cyclase, an enzyme responsible for increasing intracellular levels of cyclic adenosine monophosphate (cAMP). Elevated cAMP levels, in turn, induce relaxation of vascular smooth muscle cells, resulting in potent vasodilation, particularly in the pulmonary and systemic arterial beds. This reduces pulmonary vascular resistance and improves blood flow. Furthermore, beraprost exhibits significant antiplatelet activity by inhibiting platelet aggregation and adhesion, thereby preventing thrombus formation. Beyond these primary effects, it also demonstrates cytoprotective properties, which may contribute to its beneficial effects in vascular diseases by modulating cell proliferation and inhibiting inflammatory processes.
Commercial Brands (Alternatives)
No other brands found for this formula.